Robin R Edwards

US Patent:

20210261666, Aug 26, 2021

Filed:

May 30, 2018

Appl. No.:

16/616574

Inventors:

- Princeton NJ, US
Nils LONBERG - Woodside CA, US
Cyrus HEDVAT - New York NY, US
Raphael CLYNES - West Nyack NY, US
Darren LOCKE - Bordentown NJ, US
John P. COGSWELL - Yardley PA, US
Jeffrey JACKSON - Schwenksville PA, US
Christopher HARBISON - Hamilton NJ, US
Robin EDWARDS - Newtown PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
G01N 33/574
A61P 35/00

Abstract:

The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-Ll positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.